Clinical Evidence and Treatment Requirements Related to Heart Failure in Type 2 Diabetes Mellitus

Heart failure (HF) has emerged as a critical complication of type 2 diabetes mellitus (T2DM), warranting increased clinical attention due to its rising prevalence and significant impact on patient outcomes. The shift in focus toward HF is partly driven by the reduced incidence of atherothrombotic events following acute myocardial infarction, positioning HF as a more prominent cardiac outcome in T2DM. Additionally, landmark cardiovascular outcome trials with sodium-glucose co-transporter-2 inhibitors (SGLT2is) have demonstrated unexpected reductions in hospitalization for HF (HHF), prompting a reevaluation of risk stratification and therapeutic strategies for patients with diabetes.

Epidemiology of Heart Failure in Type 2 Diabetes

The burden of HF in T2DM is substantial. A cohort study of 1.9 million individuals revealed that HF accounted for 14.4% of initial cardiovascular (CV) events in patients with T2DM, surpassing peripheral arterial disease and other complications. The incidence of HHF varies significantly across populations: 2.4, 5.6, and 12.4 events per 1,000 person-years were reported for individuals without diabetes, those with type 1 diabetes, and those with T2DM, respectively. Notably, the prevalence of HF in Asian populations, such as the 42.3% observed in the ASIAN-HF registry, exceeds rates in non-Asian cohorts (29.3% in Caucasians). These disparities highlight the need for region-specific approaches to HF management in T2DM.

Pathophysiological Mechanisms Linking T2DM and HF

The development of HF in T2DM is multifactorial. Hyperglycemia, hypertension, microvascular dysfunction (e.g., diabetic nephropathy, autonomic neuropathy), and myocardial protein glycation contribute to structural and functional cardiac abnormalities. A distinct entity, heart failure with preserved ejection fraction (HFpEF), is particularly prevalent in T2DM. Its pathogenesis involves systemic inflammation driven by comorbidities like obesity and chronic obstructive pulmonary disease, leading to coronary microvascular endothelial inflammation. This cascade reduces nitric oxide bioavailability, cyclic guanosine monophosphate levels, and protein kinase G activity, resulting in cardiomyocyte hypertrophy, interstitial fibrosis, and diastolic dysfunction.

Glycemic Control and Heart Failure Risk

The relationship between glucose-lowering therapies and HF risk is complex. A meta-analysis of 95,502 patients across 14 trials demonstrated variable HF risks depending on treatment modalities. Peroxisome proliferator-activated receptor agonists increased HF risk by 42%, while dipeptidyl peptidase-4 inhibitors showed a 25% elevated risk. In contrast, insulin glargine and intensive glycemic or weight-loss strategies had neutral effects. These findings underscore the importance of selecting therapies that mitigate HF risk, particularly in high-risk populations.

SGLT2 Inhibitors: A Paradigm Shift in HF Management

SGLT2is have revolutionized HF management in T2DM, demonstrating consistent benefits across multiple trials:

1. EMPA-REG OUTCOME: Empagliflozin reduced three-point major adverse cardiovascular events (MACE; CV death, non-fatal myocardial infarction, non-fatal stroke) by 14% and CV death by 38%. HHF risk decreased by 35%, with benefits emerging within weeks of treatment initiation.
2. CANVAS Program: Canagliflozin lowered three-point MACE by 14% and HHF by 33%. In the CREDENCE trial, canagliflozin reduced HHF by 39% in patients with T2DM and chronic kidney disease.
3. DECLARE-TIMI 58: Dapagliflozin reduced the composite endpoint of CV death or HHF by 17%, driven by a 27% reduction in HHF.
4. DAPA-HF: Dapagliflozin decreased HF exacerbations by 26% in patients with chronic HF, regardless of diabetes status.

These trials highlight early and sustained benefits of SGLT2is on HF outcomes, independent of glycemic control or weight loss. Proposed mechanisms include hemodynamic improvements (e.g., reduced plasma volume, blood pressure, and arterial stiffness), enhanced cardiac metabolism, and direct effects on myocardial cells.

Risk Stratification and Future Directions

Identifying T2DM patients at high risk for HF remains a priority. Predictors such as elevated glycated hemoglobin (HbA1c), abnormal body mass index, physical inactivity, smoking, and prolonged diabetes duration are strongly associated with HHF. However, predictive models differ between patients with and without preexisting HF, necessitating tailored risk assessment tools.

Regional variations in treatment responses also warrant attention. Subgroup analyses suggest that Asian populations may derive greater CV benefits from SGLT2is, though this requires confirmation in dedicated studies. Furthermore, the integration of cardiometabolic medicine—a discipline combining endocrinology, cardiology, and preventive care—is critical for managing the interplay between T2DM, obesity, and CV disease.

Clinical Implications and Guidelines

Current guidelines from the European Society of Cardiology and European Association for the Study of Diabetes recommend SGLT2is as first-line therapy for T2DM patients with established CV disease or high CV risk. This endorsement reflects robust evidence for HF risk reduction and renal protection. Clinicians must prioritize HF prevention through early identification of high-risk patients, selection of cardioprotective therapies, and multidisciplinary care models.

In conclusion, HF represents a major complication of T2DM, with distinct pathophysiological pathways and therapeutic challenges. SGLT2is have emerged as a cornerstone of HF prevention and treatment, offering benefits beyond glucose control. Future efforts should focus on optimizing risk stratification, addressing regional disparities, and fostering cross-specialty collaboration to improve outcomes in this vulnerable population.

doi.org/10.1097/CM9.0000000000000732

Was this helpful?

YesNo

0 / 0